ClinicalTrials.gg
CompletedNCT03668054Updated Oct 28, 2020

Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)

A Phase 3 interventional study of Bevacizumab (Lumiere®) in Age-Related Macular Degeneration, sponsored by Laboratorio Elea Phoenix S.A.. Completed at 3 sites in Argentina. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-10-28.

Sponsored by Laboratorio Elea Phoenix S.A. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Feb 2017, registered Sep 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing bevacizumab in Macular Degeneration — none open to participants now, 2 under way, 1 of them phase 3. Bevacizumab · Macular Degeneration.

Enrollment
32nd of 40
22 · median 71
Started
2017
the only one that year
Phase 3
20 of 43
none open now
Registered
33rd of 43
by date

Among the 43 studies testing bevacizumab in Macular Degeneration, this one is the 32nd largest by enrollment of the 40 interventional ones that give a count, is the only one that started in 2017, is one of 20 in phase 3, and was the 33rd registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

None of the 43 studies testing bevacizumab in Macular Degeneration is open now. The open studies under Macular Degeneration, anywhere →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 43 studies testing bevacizumab in Macular Degeneration as a file.
02

Study summary

The purpose of this clinical trial is to evaluate the safety and clinical effectiveness of intravitreal bevacizumab (Lumiere®) in the single-dose form, for the treatment of patients with wet AMD.

Read the detailed description

Age-related macular degeneration is the main cause of severe vision loss in patients over 65 years of age. There is solid evidence of the efficacy and safety of bevacizumab in the treatment of wet AMD. However, it has not been registered for such indication yet.

In response to the need for a proper adaptation, Lumiere® has been developed in a single-dose, sterile dosage containing bevacizumab 5 mg/vial in 0.2 mL injectable solution.

This adaptation is intended to assure intravitreal administration avoiding the risk of contamination and potential adverse consequences, such as endophthalmitis and blindness, associated to reutilization or repackaging of bevacizumab vials for oncological use.

03

Conditions studied

  • Age-Related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 50 years of age diagnosed with wet age-related macular degeneration having indication of antiangiogenic therapy.
  • Both genders.
  • Subjects able to give .

Exclusion criteria

Exclusion Criteria:

  • Patients with to receive bevacizumab:

    • to the active ingredient or to some of the formula .
    • Hypersensitivity to products derived from CHO cells or to other human recombinant antibodies or humanized antibodies.
  • Patients having received intravitreal antiangiogenic therapy prior to wet AMD treatment.
  • Patients receiving previous systemic antiangiogenic therapy.
  • Wet AMD in the healing period or disciform scar.
  • Pregnant, breastfeeding or childbearing-aged women.
  • Any person with choroidal neovascularization not associated to wet AMD.
  • History of retinal or intraocular surgery in the affected eye in the last three months.
  • Vitrectomy in the affected eye.
  • Any significant ocular infection, active or suspected, having compromised or able to compromise the eye to be studied.
  • Ocular inflammatory disease.
  • Myopia exceeding -8 diopters.
  • Extensive subfoveal subretinal hemorrhage > 2 papillary diameter (PD).
  • Coexistence of other severe ocular diseases: uncontrolled ocular hypertension, terminal glaucoma, diabetic retinopathy, retinal vein thrombosis, optic atrophy.
  • History of stroke or myocardial infarction in the last 6 months.
  • Patients with coagulopathies.
  • Patients physically or mentally disabled to participate in such visual tests.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Bevacizumab (Lumiere®)

    Dosage form: intravitreal single dose vial. Dosage: 0.05ml (1.25 mg) Frequency: monthly injections (up to 6 doses)

    Drug: Bevacizumab (Lumiere®)

Interventions

  • The first three doses of bevacizumab (Lumiere®) were administered via intravitreal injection on a monthly basis. A safety evaluation was conducted in the first month. Following the first three doses, continuation of the treatment (up to 6 doses) was decided according to response.

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events codified using MedDRA.

    Register reports of drug related adverse events and compare them with prevalence in the literature after intravitreal bevacizumab (Lumiere®) in the single-dose form, for the treatment of patients with neovascular AMD.

    Time frame: 6 months

Secondary outcomes

  1. Number of participants with changes in visual acuity using the ETDRS charts in patients with wet AMD.

    Time frame: 6 months

  2. Number of participants with changes in retinal thickness as assessed by OCT in patients with wet AMD.

    Time frame: 6 months

07

Study locations

3 sites
  • Consultorios Médicos Dr. Benisek
    Buenos Aires, 1636, Argentina
  • Instituto Scorsetti S.A.
    Buenos Aires, 1636, Argentina
  • Consultorios Médicos / Clínica de Cirugía Especializada S.A. (CCE)
    Buenos Aires, Argentina
08

References and documents

Publications

  • Benisek DA, Manzitti J, Scorsetti D, Rousselot Ascarza AM, Ascarza AA, Gomez Rancano D, Quercia R, Ramirez Gismondi M, Carpio Total MA, Scorsetti ML, Spitzer E, Lombas C, Deprati M, Penna MI, Fernandez F, Tinelli MA. Safety and clinical effectiveness of intravitreal administration of bevacizumab (Lumiere(R)) in patients with neovascular age-related macular degeneration. Exp Ther Med. 2020 Dec;20(6):162. doi: 10.3892/etm.2020.9291. Epub 2020 Oct 9. PubMed 33093900 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in May 2018, 15 months.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 15 months is below that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2018
First posted
Sep 12, 2018
StartActual
Feb 7, 2017
Primary completionActual
May 30, 2018
CompletionActual
May 30, 2018
Last update
Oct 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03668054
Lead sponsor
Laboratorio Elea Phoenix S.A.
Responsible party
Sponsor
First posted
Sep 12, 2018
Start date
Feb 7, 2017
Primary completion
May 30, 2018
Completion
May 30, 2018
Last update
Oct 28, 2020

Study contacts

Daniel Benisek, MD
principal investigator · Consultorios Médicos Dr. Benisek

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion